AbbVie Invests $1.4 Billion in New AI-Driven Manufacturing Campus in North Carolina
- AbbVie invests $1.4 billion in a new manufacturing campus in North Carolina.
- The facility will enhance production in immunology, neuroscience, and oncology.
- AbbVie’s largest investment signals commitment to innovation and job creation in the U.S. healthcare sector.
AbbVie (NYSE: ABBV) has announced a major milestone in its manufacturing strategy, revealing a $1.4 billion investment to build a new pharmaceutical manufacturing campus in Durham, North Carolina. This will mark the company's largest-ever capital investment in a single site, underscoring AbbVie's commitment to enhancing its production capacities for immunology, neuroscience, and oncology treatments. The strategic location near Research Triangle Park is chosen for its skilled workforce and significant potential for expansion.
Construction is expected to initiate in 2026, with the campus projected to be completed by the end of 2028. The facility aims to integrate advanced manufacturing processes, incorporating artificial intelligence technologies to optimize production efficiency. Upon completion, the new campus is anticipated to create approximately 734 jobs, benefiting the local economy while reinforcing AbbVie’s position as an industry leader committed to innovation.
This investment aligns with AbbVie’s broader $100 billion commitment to U.S. research and development over the next decade, showcasing its dedication to enhancing the pharmaceutical supply chain. Robert A. Michael, Chairman and CEO of AbbVie, highlights this investment as pivotal not just for the company but also for fostering partnerships within the North Carolina community, reinforcing its role in supporting local economic growth.
In addition to this significant investment, AbbVie is navigating regulatory environments with the recent Complete Response Letter from the U.S. FDA regarding its Botulinum Toxin product. The letter requests additional information on manufacturing processes, though it does not raise any concerns about safety or efficacy. AbbVie expresses readiness to comply with the FDA's requirements and remains committed to delivering innovative healthcare solutions.